DBV Technologies S.A.

Report azionario NasdaqCM:DBVT

Capitalizzazione di mercato: US$973.8m

DBV Technologies Salute del bilancio

Criteri Salute finanziaria verificati 5/6

DBV Technologies ha un patrimonio netto totale di $207.9M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $266.4M e $58.5M.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessin/a
ContantiUS$229.20m
Patrimonio nettoUS$207.90m
Totale passivitàUS$58.50m
Totale attivitàUS$266.40m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Seeking Alpha • Sep 21

FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial

French biotech DBV Technologies (NASDAQ:DBVT) on Wednesday said the U.S. FDA had put a partial clinical hold on its phase 3 clinical study evaluating its Viaskin Peanut patch for the treatment of peanut allergy in children aged 4 through 7. The FDA specified certain changes to elements of the protocol of the trial, called VITESSE. "Within the FDA’s communication, the modifications address design elements, including the statistical analysis of adhesion, minimum daily wear time and technical alignments in methods of categorizing data, to meet study objectives as well as the total number of trial participants on active treatment," DBVT said in a statement. The company had not yet begun the screening or recruitment of subjects in the study. DBVT said the partial clinical hold was only for the VITESSE trial and did not impact any other ongoing clinical studies. U.S.-listed shares of DBVT earlier closed +4.3% at $2.21.
Seeking Alpha • Aug 01

DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M

DBV Technologies press release (NASDAQ:DBVT): Q2 GAAP EPS of -$0.35 misses by $0.03. Revenue of $1.53M beats by $0.29M. Shares +3.19% AH.
Seeking Alpha • Jul 07

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

DBV Technologies is a French company traded on Nasdaq which is developing treatments for food allergies. Their technology is a patch that delivers a very small daily dose of the allergen to desensitize the patient. The company previously received a CRL due to issues with the adhesion properties of their patch. The Phase 3 EPITOPE trial met the primary endpoint with a good safety profile. FDA feedback on the regulatory path is the next critical catalyst for the company. DBV Technologies (DBVT) is developing an epicutaneous (on the skin) delivery system for the treatment of food allergies including peanuts and milk. After completing a Phase 3 trial in children ages 4-11, the company received a CRL from the FDA for their Viaskin peanut patch due to concerns about patch adhesion. The company redesigned the patch and will need to run a new Phase 3 trial using the modified patch for this age group. Recently, using the unmodified patch, the EPITOPE study met the primary endpoint in children ages 1-4. DBV Technologies is well capitalized after a recent raise that occurred after the EPITOPE readout. There is considerable uncertainty about the regulatory path but longer term these assets, if approved have significant value. Peanut Allergies and Treatment Options There are more than one million children in the US with peanut allergies. The prevalence in babies is increasing and as many as 5% of babies have a peanut allergy. Avoidance of peanuts is the primary strategy but accidental exposure can result in severe reactions. Allergy treatments gradually increase the quantity of allergen that a child is exposed to. The goal of treatment is to desensitize the child and increase the quantity of peanut that elicits an allergic reaction. There are no FDA-approved treatments for peanut allergies in children ages 1-3. At age 4, children would become eligible for Palforzia which is an oral immunotherapy. It is newly approved and can only be prescribed by a trained allergist and requires an FDA mandated risk mitigation plan due to the risk of anaphylaxis. In the Palforzia program, under the supervision of a trained physician, children ingest increasing amounts of peanut protein. Dose escalation occurs in a certified physician’s office. At dose escalation, 67 % of patients reported abdominal pain, 36.5% experienced vomiting, 32% reported nausea and 31% reported oral itching. There was a 9.4 % rate of anaphylaxis during dose escalation and 8.7% during maintenance dosing. At the end of treatment, 67% of Palforzia patients could tolerate a 600 mg dose of peanuts. (600 mg is approximately 2 peanuts). The EPITOPE study met the primary endpoint Toddlers aged 1-3 who have a peanut allergy were enrolled in the clinical trial. On a daily basis, their caregivers applied a Viaskin peanut patch. The patch at the highest dose contains 250 micrograms of peanut protein which is a very, very small amount of peanut protein. (A microgram is one thousandth of an mg.) The EPITOPE trial was one year in duration. 244 toddlers received treatment and 118 received placebo. At baseline and at the end of treatment, toddlers received a food challenge to determine their eliciting dose. The eliciting dose is the amount of peanut that causes allergic symptoms. At the end of treatment, patients who were successfully treated made the improvements shown in the chart below. Before Treatment After Treatment Eliciting dose less than or equal to 10 mg Eliciting dose greater than or equal to 300 mg Eliciting dose greater than 10 mg Eliciting dose greater than or equal to 1000 mg Source: DBV Technologies 67% of children treated met the "success" response criteria at 12 months. In comparison, 33.5 % of placebo treated children met the endpoint. (Note: The placebo response was likely a result of a self resolving peanut allergy.) This result was statistically significant and the primary endpoint was met. In the trial, there was one SAE which was swelling around the eye. The most common side effect was a reaction at the site where the patch was applied. 22.5 % of the children experienced a site reaction that was severe as compared to 8.5% of placebo patients. These reactions decreased during the one year treatment period. Eight children discontinued treatment due to side effects. Four children (1.6%) treated with Viaskin Peanut experienced an anaphylactic reaction that was determined to be or may have been related to treatment. None of these anaphylactic reactions were serious. Three of these reactions resolved with epinephrine and one without epinephrine. A long term open label extension study is underway. Revenue Projections

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $246.7M ) di DBVT superano le sue passività a breve termine ( $51.8M ).

Passività a lungo termine: Le attività a breve termine di DBVT ( $246.7M ) superano le sue passività a lungo termine ( $6.7M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: DBVT è esente da debiti.

Riduzione del debito: DBVT non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 0.6%.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: DBVT ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: DBVT ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a crescere ai tassi storici del 6.8 % ogni anno.

Scoprire le aziende sane

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/08 11:55
Prezzo dell'azione a fine giornata2026/07/08 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

DBV Technologies S.A. è coperta da 16 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Tazeen AhmadBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jonathan WollebenCitizens JMP Securities, LLC